



- 23 -

WHAT IS CLAIMED IS:

1. Antiatherosclerotic agents represented by Formulas I or II:




I



II

wherein

R is



wherein R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>13</sub>, and R<sub>14</sub> are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms;

R<sub>6</sub>, and R<sub>7</sub> are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or CH<sub>2</sub>COOR<sub>8</sub>, where R<sub>8</sub> is a lower alkyl of 1-6 carbon atoms; and

X is O or S;

R<sub>1</sub> is hydrogen or a lower alkyl of 1-6 carbon atoms;

R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are each, independently, hydrogen or halogen; and


R<sub>5</sub> is a lower alkyl of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof.

- 24 -

2. The antiatherosclerotic agent of claim 1, wherein:

R is



5 wherein:

R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>13</sub>, and R<sub>14</sub> are each, independently, hydrogen or lower alkyl of 1 to 6 carbon atoms;

R<sub>6</sub> and R<sub>7</sub> are, each independently, lower alkyl of 1 to 6 carbon atoms; and

X is O or S;

10 R<sub>1</sub> is hydrogen;

R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are each, independently, hydrogen or halogen; and

R<sub>5</sub> is a lower alkyl of 1 to 6 carbon atoms;

or a pharmaceutically acceptable salt thereof.

✓ 15 3. The antiatherosclerotic agent of claim 1, which is 1-(5-chloro-2-methyl-phenyl)-3-(thiazol-2-yl)-thiourea.

4. The antiatherosclerotic agent of claim 1, which is 1-(benzothiazol-2-yl)-3-(5-chloro-2 methyl-phenyl)-thiourea.

20

5. The antiatherosclerotic agent of claim 1, which is 1-(5-chloro-2-methyl-phenyl)-3-(naphtho[2,1-d]thiazol-2-yl)-thiourea.


✓ 6. The antiatherosclerotic agent of claim 1, which is 1-(5-chloro-2-methyl-phenyl)-  
 25 3-(4-methyl-oxazol-2-yl)-thiourea.

- 25 -


7. The antiatherosclerotic agent of claim 1, which is 1-(5-chloro-2-methyl-phenyl)-3-(5-methyl-[1,3,4]thiadiazol-2-yl)-thiourea.
- 5 8. The antiatherosclerotic agent of claim 1, which is 1-(5-chloro-2-methyl-phenyl)-3-(1-methyl-1H-pyrazol-3-yl)-thiourea.
9. The antiatherosclerotic agent of claim 1, which is 1-(5-chloro-2-methyl-phenyl)-3-(1H-pyrazol-3-yl)-thiourea.
- 10 10. The antiatherosclerotic agent of claim 1, which is 1-(5-chloro-2-methyl-phenyl)-3-(1,3,5-trimethyl-1H-pyrazol-4-yl)-thiourea.
- ✓ 11. The antiatherosclerotic agent of claim 1, which is 1-(5-chloro-2-methyl-phenyl)-15 3-(4-methyl-thiazol-2-yl)-thiourea.
- ✓ 12. The antiatherosclerotic agent of claim 1, which is 1-(5-chloro-2-methyl-phenyl)-3-(4,5-dimethyl-thiazol-2-yl)thiourea.
- 20 ✓ 13. The antiatherosclerotic agent of claim 1, which is {2-[3-(5-chloro-2-methyl-phenyl)-thioureido]-thiazol-4-yl}-acetic acid ethyl ester.
14. The antiatherosclerotic agent of claim 1, which is 1-(5-chloro-2-methyl-phenyl)-3-(3-methyl-isothiazol-5-yl)-thiourea.
- 25 15. The antiatherosclerotic agent of claim 1, which is 1-(5-chloro-2-methyl-phenyl)-3-(2-methyl-benzothiazol-5-yl)-thiourea.
16. The antiatherosclerotic agent of claim 1, which is 1-(5-chloro-2-methyl-phenyl)-30 3-(5-ethyl-[1,3,4]thiadiazol-2-yl)-thiourea.
17. The antiatherosclerotic agent of claim 1, which is 1-(2-chloro-6-methyl-phenyl)-3-(1,3,5-trimethyl-1H-pyrazol-4-yl)-thiourea.

- 26 -

18. The antiatherosclerotic agent of claim 1, which is 1-(4-chloro-2-methyl-phenyl)-3-(1,3,5-trimethyl-1H-pyrazol-4-yl)-thiourea.
- ✓ 19. The antiatherosclerotic agent of claim 1, which is 1-(4-chloro-2-methyl-phenyl)-3-(4-methyl-oxazol-2-yl)-thiourea.
- ✓ 20. The antiatherosclerotic agent of claim 1, which is 1-(2-chloro-6-methyl-phenyl)-3-(4-methyl-oxazol-2-yl)-thiourea.
- 10 21. The antiatherosclerotic agent of claim 1, which is 3-(5-chloro-2-methyl-phenyl)-1-ethyl-1-(1,3,5-trimethyl-1H-pyrazol-4-yl)-thiourea.
22. The antiatherosclerotic agent of claim 1, which is (E)-1-(5-chloro-2-methyl-phenyl)-2-methyl-3-(1,3,5-trimethyl-1H-pyrazol-4-yl)-isothiouraea.
- 15 23. The antiatherosclerotic agent of claim 1, which is 3-(5-chloro-2-methyl-phenyl)-1-ethyl-2-methyl-1-(1,3,5-trimethyl-1H-pyrazol-4-yl)-isothiouraea.
24. A method of treating atherosclerosis in a mammal in need thereof, which
- 20 comprises administering to said mammal an anti-atherosclerotic effective amount of a compound represented by Formulas I or II:



I




II

- 27 -

wherein

R is




wherein R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>13</sub>, and R<sub>14</sub> are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms;

R<sub>6</sub>, and R<sub>7</sub> are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or CH<sub>2</sub>COOR<sub>8</sub>, where R<sub>8</sub> is a lower alkyl of 1-6 carbon atoms; and


X is O or S;

- 15 R<sub>1</sub> is hydrogen or a lower alkyl of 1-6 carbon atoms;  
 R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are each, independently, hydrogen or halogen; and  
 R<sub>5</sub> is a lower alkyl of 1-6 carbon atoms;  
 or a pharmaceutically acceptable salt thereof.

- 20 25. A method of elevating the HDL concentration in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound represented by Formulas I or II:



I




II

- 28 -

wherein

R is




wherein R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>13</sub>, and R<sub>14</sub> are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms;

R<sub>6</sub>, and R<sub>7</sub> are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or CH<sub>2</sub>COOR<sub>8</sub>, where R<sub>8</sub> is a lower alkyl of 1-6 carbon atoms; and


X is O or S;

- 15 R<sub>1</sub> is hydrogen or a lower alkyl of 1-6 carbon atoms;  
 R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are each, independently, hydrogen or halogen; and  
 R<sub>5</sub> is a lower alkyl of 1-6 carbon atoms;  
 or a pharmaceutically acceptable salt thereof.

- 20 26. A method of treating dyslipoproteinemia in a mammal in need thereof, which comprises administering to said mammal an anti-dyslipoproteinemic effective amount of a compound represented by Formulas I or II:



I




II

- 29 -

wherein

R is





wherein R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>13</sub>, and R<sub>14</sub> are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms;

R<sub>6</sub>, and R<sub>7</sub> are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or CH<sub>2</sub>COOR<sub>8</sub>, where R<sub>8</sub> is a lower alkyl of 1-6 carbon atoms; and

X is O or S;

- 15 R<sub>1</sub> is hydrogen or a lower alkyl of 1-6 carbon atoms;  
 R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are each, independently, hydrogen or halogen; and  
 R<sub>5</sub> is a lower alkyl of 1-6 carbon atoms;  
 or a pharmaceutically acceptable salt thereof.


- 20 27. A method of treating cardiovascular disease in a mammal in need thereof, which comprises administering to said mammal an anti-cardiovascular disease effective amount of a compound represented by Formulas I or II:



- 30 -

wherein

R is




wherein R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>13</sub>, and R<sub>14</sub> are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms;

R<sub>6</sub>, and R<sub>7</sub> are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or CH<sub>2</sub>COOR<sub>8</sub>, where R<sub>8</sub> is a lower alkyl of 1-6 carbon atoms; and


X is O or S;

- 15 R<sub>1</sub> is hydrogen or a lower alkyl of 1-6 carbon atoms;  
 R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are each, independently, hydrogen or halogen; and  
 R<sub>5</sub> is a lower alkyl of 1-6 carbon atoms;  
 or a pharmaceutically acceptable salt thereof.

- 20 28. A pharmaceutical composition, which comprises an antiatherosclerotic agent represented by Formulas I or II:



I




II



- 31 -

wherein

R is



wherein R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>13</sub>, and R<sub>14</sub> are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms;

R<sub>6</sub>, and R<sub>7</sub> are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or CH<sub>2</sub>COOR<sub>8</sub>, where R<sub>8</sub> is a lower alkyl of 1-6 carbon atoms; and

X is O or S;

R<sub>1</sub> is hydrogen or a lower alkyl of 1-6 carbon atoms;

R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are each, independently, hydrogen or halogen; and

R<sub>5</sub> is a lower alkyl of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof.